Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14832249 | 1.00 | IDH1 (0.75) | IDH1 | |
| SCHEMBL19700742 | 0.89 | IDH1 (0.81) | IDH1 | |
| SCHEMBL21378549 | 0.89 | IDH1 (0.81) | IDH1 | |
| SCHEMBL21378548 | 0.89 | IDH1 (0.81) | IDH1 | |
| SCHEMBL19191980 | 0.86 | IDH1 (0.54) | IDH1 | |
| SCHEMBL14831532 | 0.86 | IDH1 (1.00) | IDH1 | |
| SCHEMBL14831533 | 0.86 | IDH1 (1.00) | IDH1 | |
| SCHEMBL14831202 | 0.84 | IDH1 (0.76) | IDH1 | |
| SCHEMBL15954603 | 0.83 | IDH1 (0.73) | IDH1 | |
| SCHEMBL19701037 | 0.83 | IDH1 (0.78) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771337-B1 | 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2771337-B1 | 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-8957068-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2771337-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| WO-2013046136-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235620-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3A, IDH3B | IDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.